Merck KGaA, Darmstadt, Germany, Builds on Leadership in Head and Neck Cancer Through Worldwide Licensing Agreement with Debiopharm for Pivotal-Stage XevinapantPRNewsWire • 03/01/21
Is Merck Stock A Buy As The Company Puts Up $1.85 Billion In Pandion Buy?Investors Business Daily • 02/26/21
Pandion Therapeutics Surges To Record High On Merck's $1.85 Billion BuyoutInvestors Business Daily • 02/25/21
PANDION ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of PAND and Encourages Investors to Contact the FirmGlobeNewsWire • 02/25/21
Pandion Therapeutics soars 132% after Merck agrees to buy the biotech for $1.85 billionBusiness Insider • 02/25/21
Merck Agrees To Acquire Pandion Therapeutics Amid Expectations Of Rebound In Pharma M&A This YearForbes • 02/25/21